SomaLogic And FDA Will Streamline Biosimilar Development

Agreement Aims To Identify Pharmacodynamic Biomarkers For Reference Biologics

 
• By Dean Rudge
Washington, D.C., USA- January 13, 2020: FDA Sign outside their headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.
SomaLogic's proteomic strategy, if successful, could reduce the need for comparative clinical studies • Source: Shutterstock

More from Biosimilars

More from Products